StockData
Dogwood Therapeutics, Inc. logo

Dogwood Therapeutics, Inc. (DWTX) company profile

DWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$1.08+0.02 (+1.89%)

Close on Nov 17, 2026Market cap $36.71MP/E –Yield –

About Dogwood Therapeutics

Pharmaceutical Preparations, SIC 2834

This clinical-stage biopharmaceutical company discovers and develops novel therapeutic candidates aimed at treating neuropathy and chronic pain disorders. Its development pipeline features Halneuron, a late-stage non-opioid analgesic derived from tetrodotoxin that selectively inhibits Nav 1.7 sodium channels to alleviate chemotherapy-induced neuropathic pain. Additional programs include SP16, a synthetic anti-inflammatory peptide designed to promote nerve regeneration and reduce nerve damage, alongside preclinical and clinical-stage antiviral therapies, IMC-1 and IMC-2, targeting functional somatic syndromes such as fibromyalgia and Long-COVID. Upon achieving regulatory approval, the company intends to commercialize its pipeline through pharmaceutical distribution partnerships targeting primary care physicians, oncologists, and anesthesiologists.

The enterprise operates as a development-stage entity without commercial revenue and conducts operations across North America and international territories through subsidiaries including Wex Pharmaceuticals, Inc. It oversees clinical development programs across multiple locations, including Phase 2b trial sites in the United States. Technical development activities incorporate contract research and manufacturing relationships with an overseas active ingredient supplier and a Canadian fill-and-finish facility. The provided text does not identify corporate headquarters.

Summary of the business section of Dogwood Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Dogwood Therapeutics, Inc.
Headquarters
Alpharetta, GA
Address
44 Milton Avenue 30009
Phone
(866) 620-8655
Website
dwtx.com
Employees
8, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Forvis Mazars, LLP, Atlanta, Georgia

Stock & identifiers

Ticker
DWTX
Former tickers
VIRI until Oct 30, 2024
Exchange
Nasdaq
IPO date
Dec 18, 2020
Shares outstanding
34M, Aug 13, 2026
Public float
$8.09M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-25 reverse, Oct 9, 2024
SEC CIK
1818844
CUSIP
92829J203
ISIN
US92829J2033
FIGI
BBG00X0SZKJ2
Share class FIGI
BBG00X0SZLB8
EIN
85-4314201

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Gregory Scott DuncanCHIEF EXECUTIVE OFFICER, Director57,461
Roger Michael GendreauCHIEF MEDICAL OFFICER–
Ralph GrosswaldSVP OF OPERATIONS–
Angela WalshChief Financial Officer3,000
Inc. ConjointDirector24,664,971
Ltd SealbondDirector28,763,331
Life Sciences Intl (Holdings) Inc CKDirector–
David R. KeeferDirector12,808
John C. ThomasDirector1,000
Richard James WhitleyDirector700
La Rosa Abel DeDirector4,000

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.34M$2.62M$1.29M$17–
FY2024$881.22K$751.88K$437.97K$29–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Greg Duncan
Chairman and Chief Executive Officer
$577.00K$2.40M$317.35K$49.78K$3.34M+280%
R. Michael Gendreau, MD, PhD
Chief Medical Officer
$366.08K$779.14K$146.43K$38.62K$1.33M+160%
Angela Walsh
Chief Financial Officer
$300.91K$779.14K$128.76K$43.24K$1.25M+244%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 18, 2020
Offer price
$10.00
Securities offered
3,000,000
Gross proceeds
$30.00M
Exchange
Nasdaq
First trading day
Dec 17, 2020
First-day close
$16.71+67.1%
Lock-up ends (est.)
Jun 15, 2021

“We are offering 3,000,000 shares of our common stock at an initial public offering price of $10.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had eight full-time employees and no part-time employees with five employees working in the U.S.”

Corporate history

Events identified from SEC filings

DateEventDetails
Nov 21, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 15, 2024Name changeName changed from Virios Therapeutics, Inc. to Dogwood Therapeutics, Inc.
Oct 7, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 12, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 7, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 7, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 2, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 3, 2022Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 18, 2020IPOInitial public offering priced (424B4 prospectus)
Dec 16, 2020ListingRegistration of securities on an exchange (Form 8-A)
Dec 16, 2020Name changeName changed from Virios Therapeutics, LLC to Virios Therapeutics, Inc.

See a number that looks wrong?